Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGuillermo Montalban‐BravoThe University of Texas MD Anderson Cancer CenterMSMahesh SwaminathanThe University of Texas MD Anderson Cancer CenterTKTapan M. KadiaThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Overview

Cohort study shows allogeneic stem cell transplantation improves outcomes in chronic myelomonocytic leukemia, indicating significance of mutations and conditioning.

Key Points

  • This research aims to evaluate the outcomes of allogeneic stem cell transplantation in chronic myelomonocytic leukemia patients.
  • Cohort of 855 newly diagnosed CMML patients assessed between 2000-2023.
  • Outcomes measured using time-to-event analysis and cumulative incidence methods.
  • Multivariate analysis conducted using Cox proportional hazards regression.
  • 13% of patients underwent allogeneic stem cell transplantation.
  • Median overall survival was 57.7 months for CMML, with relapse incidence at 33%.
  • Graft-versus-host disease affected 60% of patients post-transplant.

Cite This Study

Montalban‐Bravo et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d60dhttps://doi.org/10.1182/blood-2025-4294
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients2025
  2. 2Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes2025 · 1 citations
  3. 3Myeloablative and Reduced Intensity Allogeneic Transplant in Patients with Myeloproliferative Neoplasms.2025
  4. 4Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors2025
  5. 5Myeloproliferative neoplasm driver mutations (JAK2/CALR/MPL) in chronic myelomonocytic leukemia are associated with an increased risk of blast transformation2025